Significance of the Pretreatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting the Response to Neoadjuvant Chemotherapy and Survival Rates in Extremity Osteosarcoma: A Multicentre Prospective Study.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2023-12-01 Epub Date: 2024-01-02 DOI:10.1080/07357907.2023.2283456

Amir Mohammad Arefpour, Maryam Garousi, Ahmad Foroughi, Saeed Hosseini, Mohadeseh Shahin, Seyed Alireza Javadinia

{"title":"Significance of the Pretreatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting the Response to Neoadjuvant Chemotherapy and Survival Rates in Extremity Osteosarcoma: A Multicentre Prospective Study.","authors":"Amir Mohammad Arefpour, Maryam Garousi, Ahmad Foroughi, Saeed Hosseini, Mohadeseh Shahin, Seyed Alireza Javadinia","doi":"10.1080/07357907.2023.2283456","DOIUrl":null,"url":null,"abstract":"Objectives: We aimed to assess the effects of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on the response to neoadjuvant chemotherapy and survival rates in patients with extremity osteosarcoma.Patients and methods: Patients with high-grade osteosarcoma admitted to oncologic centers affiliated with Iran University of Medical Sciences, Tehran, Iran from 2015 to 2021 were evaluated retrospectively to assess the impact of complete blood count-related parameters on the pathologic response after neoadjuvant chemotherapy. Then, patients were followed up prospectively to evaluate the survival rates. All patients received at least three cycles of cisplatin/doxorubicin regimen, preoperatively. In this study, the cut-off values for high neutrophil-to-lymphocyte and high platelet-to-lymphocyte ratio were considered 3.28 and 128, respectively.Results: One hundred eighty-six patients were enrolled. Patients with high neutrophil-to-lymphocyte ratio and high platelet-to-lymphocyte ratio had a significantly lower overall survival rates (20.7 [95% CI 18-23.5] month vs. 34.6 [95% CI 33.2-36], p = 0.003 and 21.9 [95% CI 20.2-23.6] month versus 35.3 [95% CI 33.9-36.7], p = 0.002; respectively). Moreover, disease-free survival of patients with high platelet-to-lymphocyte ratio was worse than patients with low platelet-to-lymphocyte ratio (20.4 [95% CI 18.4-22.4] month vs. 32.7 [95% CI 30.8-34.7], p = 0.02).Conclusion: Our study showed that neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios at the baseline can predict the survival of patients with high-grade osteosarcoma.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"816-820"},"PeriodicalIF":1.8000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2023.2283456","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: We aimed to assess the effects of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on the response to neoadjuvant chemotherapy and survival rates in patients with extremity osteosarcoma.

Patients and methods: Patients with high-grade osteosarcoma admitted to oncologic centers affiliated with Iran University of Medical Sciences, Tehran, Iran from 2015 to 2021 were evaluated retrospectively to assess the impact of complete blood count-related parameters on the pathologic response after neoadjuvant chemotherapy. Then, patients were followed up prospectively to evaluate the survival rates. All patients received at least three cycles of cisplatin/doxorubicin regimen, preoperatively. In this study, the cut-off values for high neutrophil-to-lymphocyte and high platelet-to-lymphocyte ratio were considered 3.28 and 128, respectively.

Results: One hundred eighty-six patients were enrolled. Patients with high neutrophil-to-lymphocyte ratio and high platelet-to-lymphocyte ratio had a significantly lower overall survival rates (20.7 [95% CI 18-23.5] month vs. 34.6 [95% CI 33.2-36], p = 0.003 and 21.9 [95% CI 20.2-23.6] month versus 35.3 [95% CI 33.9-36.7], p = 0.002; respectively). Moreover, disease-free survival of patients with high platelet-to-lymphocyte ratio was worse than patients with low platelet-to-lymphocyte ratio (20.4 [95% CI 18.4-22.4] month vs. 32.7 [95% CI 30.8-34.7], p = 0.02).

Conclusion: Our study showed that neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios at the baseline can predict the survival of patients with high-grade osteosarcoma.

查看原文本刊更多论文

预处理中性粒细胞/淋巴细胞比率和血小板/淋巴细胞比率在预测四肢骨肉瘤对新辅助化疗的反应和生存率中的意义:一项多中心前瞻性研究。

目的探讨预处理中性粒细胞/淋巴细胞比率和血小板/淋巴细胞比率对肢体骨肉瘤患者新辅助化疗反应和生存率的影响。患者和方法回顾性评估2015 - 2021年在伊朗德黑兰伊朗医科大学附属肿瘤中心收治的高级别骨肉瘤患者，评估全血细胞计数相关参数对新辅助化疗后病理反应的影响。然后，对患者进行前瞻性随访，评估生存率。所有患者术前均接受至少三个周期的顺铂/阿霉素方案治疗。中性粒细胞与淋巴细胞比值高和血小板与淋巴细胞比值高的临界值分别为3.28和128。结果共纳入186例患者。中性粒细胞与淋巴细胞比值高和血小板与淋巴细胞比值高的患者总生存率显著降低(20.7 [95%CI 18 ~ 23.5]个月vs 34.6 [95%CI 33.2 ~ 36]个月，p = 0.003; 21.9 [95%CI 20.2 ~ 23.6]个月vs 35.3 [95%CI 33.9 ~ 36.7]个月，p = 0.002;分别)。此外，血小板与淋巴细胞比值高的患者的无病生存期比血小板与淋巴细胞比值低的患者差(20.4 [95%CI 18.4 ~ 22.4]个月vs 32.7 [95%CI 30.8 ~ 34.7]个月，p = 0.02)。结论我们的研究表明中性粒细胞与淋巴细胞和血小板与淋巴细胞的基线比率可以预测高级别骨肉瘤患者的生存。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.